The J.P. Morgan View Growth versus virus now, vaccine versus virus later –an update on a conflict and a hope Cross-asset strategy: The dominant macro narrative of the past several weeks hasn’t changed much, and neither has the pattern of uneven advances across and within global markets. The reality of a booming economy versus the threat of a spending retrenchment…
“Anyone can get lucky for a short period of time. But consistent outperformance over long periods is probably evidence...
After a 5-month long downtrend in market volatility and an exceptional rally off of the March lows, it has...
Good Sunday and welcome back Finom Group investors and traders. “Steady as she goes” or “So far so good?”...
Welcome back investors! In this weekend’s macro-market Research Report, we intend to catch-up on the markets’ year-to-date performance and...
Divergence! A one-word sentence used appropriately to describe last week’s trading action where the Dow was significantly lower than...
Patient, tactical, resourced, and disciplined investors are always rewarded! Manage those characteristics and you will “massage” your returns higher!...
Leading economic indicators continue to slip lower. Yet, bulls, who rightly counseled against “fighting the Fed” during the free-money...
JPM Market Recap
$0.00
JPM Research Note
$0.00
JP Morgan Market Volatility Report
$0.00
MarketWatch.com – Top Stories
